** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket
** Brokerage H.C. Wainwright starts coverage with "buy" rating, sets PT at $36
** The new price target is more than double the stock's last close
** Brokerage says a late-stage study of "underappreciated" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025
** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes
** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study
** Up to last close, stock up 14.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。